➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Moodys
Dow
Baxter
Boehringer Ingelheim

Last Updated: February 24, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FLUDEOXYGLUCOSE F18

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Fludeoxyglucose F18

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00001568 Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Modal Completed National Cancer Institute (NCI) Phase 2 1997-02-01 Positron Emission Tomography (PET scanning) is performed using a total dose of less than 50 mRad per patient visit. Fludeoxyglucose F 18 (FDG) is injected intravenously over 2 min. Initial dynamic images will be obtained over the heart. Emission imaging will work from the midcervical region down to the perineal region. For CEA scanning, radiolabeled antibody, arcitumomab (IMMU-4), is injected intravenously over 5 min. A single photon emission computed tomography (SPECT) transmission scan is performed over the same regions as the emission scans. Total dose from transmission scans should be no more than 20 mRad per patient visit. Patients then undergo exploratory laparotomy performed by two surgeons, one blinded to the results of the CEA-Scan and PET scan. At the completion of all exploration, all identified disease is biopsied for pathologic analysis and any resectable disease is removed. Patients are followed every 3 months for 1 year, every 6 months for the second year, and then after 3 years.
NCT00004152 PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma Completed National Cancer Institute (NCI) Phase 2 1999-02-01 RATIONALE: Diagnostic procedures may improve the ability to detect metastatic melanoma and to determine the extent of disease. PURPOSE: Phase II trial to evaluate the effectiveness of PET and CT scans to detect metastatic disease in patients who have stage III or stage IV melanoma.
NCT00004152 PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma Completed Memorial Sloan Kettering Cancer Center Phase 2 1999-02-01 RATIONALE: Diagnostic procedures may improve the ability to detect metastatic melanoma and to determine the extent of disease. PURPOSE: Phase II trial to evaluate the effectiveness of PET and CT scans to detect metastatic disease in patients who have stage III or stage IV melanoma.
NCT00004867 Positron Emission Tomography in Determining Stage of Esophageal Cancer Completed National Cancer Institute (NCI) N/A 1999-11-01 RATIONALE: Imaging procedures such as positron emission tomography may improve the ability to determine the stage of esophageal cancer. PURPOSE: This clinical trial is studying how well fludeoxyglucose F 18 positron emission tomography determines tumor stage in patients with esophageal cancer.
NCT00004867 Positron Emission Tomography in Determining Stage of Esophageal Cancer Completed Alliance for Clinical Trials in Oncology N/A 1999-11-01 RATIONALE: Imaging procedures such as positron emission tomography may improve the ability to determine the stage of esophageal cancer. PURPOSE: This clinical trial is studying how well fludeoxyglucose F 18 positron emission tomography determines tumor stage in patients with esophageal cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fludeoxyglucose F18

Condition Name

Condition Name for Fludeoxyglucose F18
Intervention Trials
Lymphoma 14
Lung Cancer 9
Breast Cancer 7
Sarcoma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fludeoxyglucose F18
Intervention Trials
Lymphoma 24
Carcinoma 22
Lung Neoplasms 19
Sarcoma 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fludeoxyglucose F18

Trials by Country

Trials by Country for Fludeoxyglucose F18
Location Trials
United States 983
Canada 62
Australia 12
Puerto Rico 6
New Zealand 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fludeoxyglucose F18
Location Trials
California 47
Maryland 42
Ohio 41
Pennsylvania 35
New York 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fludeoxyglucose F18

Clinical Trial Phase

Clinical Trial Phase for Fludeoxyglucose F18
Clinical Trial Phase Trials
Phase 4 2
Phase 3 13
Phase 2/Phase 3 4
[disabled in preview] 90
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fludeoxyglucose F18
Clinical Trial Phase Trials
Completed 43
Recruiting 31
Active, not recruiting 26
[disabled in preview] 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fludeoxyglucose F18

Sponsor Name

Sponsor Name for Fludeoxyglucose F18
Sponsor Trials
National Cancer Institute (NCI) 109
University of Washington 8
Sidney Kimmel Comprehensive Cancer Center 5
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fludeoxyglucose F18
Sponsor Trials
Other 117
NIH 111
Industry 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Merck
Johnson and Johnson
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.